Detailed Information on Publication Record
2022
LncRNA PVT1 is increased in renal cell carcinoma and affects viability and migration in vitro
BOHOŠOVÁ, Júlia, Marek KAŠÍK, Adéla KUBÍČKOVÁ, Karolína TRACHTOVÁ, Michal STANÍK et. al.Basic information
Original name
LncRNA PVT1 is increased in renal cell carcinoma and affects viability and migration in vitro
Authors
BOHOŠOVÁ, Júlia (703 Slovakia, belonging to the institution), Marek KAŠÍK (203 Czech Republic, belonging to the institution), Adéla KUBÍČKOVÁ (203 Czech Republic, belonging to the institution), Karolína TRACHTOVÁ (203 Czech Republic, belonging to the institution), Michal STANÍK (703 Slovakia, belonging to the institution), Alexandr POPRACH (203 Czech Republic, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution)
Edition
JOURNAL OF CLINICAL LABORATORY ANALYSIS, HOBOKEN, WILEY, 2022, 0887-8013
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.700
RIV identification code
RIV/00216224:14110/22:00127200
Organization unit
Faculty of Medicine
UT WoS
000783767200001
Keywords in English
diagnosis; long non-coding RNA; migration next-generation sequencing; proliferation; transcriptome
Tags
International impact, Reviewed
Změněno: 15/10/2024 14:46, Ing. Martina Blahová
Abstract
V originále
Background Renal cell carcinoma is difficult to diagnose and unpredictable in disease course and severity. There are no specific biomarkers for diagnosis and prognosis estimation feasible in clinical practice. Long non-coding RNAs (lncRNAs) have emerged as potent regulators of gene expression in recent years. Aside from their cellular role, their expression patterns could be used as a biomarker of ongoing pathology. Methods In this work, we used next-generation sequencing for global lncRNA expression profiling in tumor and non-tumor tissue of RCC patients. The four candidate lncRNAs have been further validated on an independent cohort. PVT1, as the most promising lncRNA, has also been studied using functional in vitro tests. Results Next-generation sequencing showed significant dysregulation of 1163 lncRNAs; among them top 20 dysregulated lncRNAs were AC061975.7, AC124017.1, AP000696.1, AC148477.4, LINC02437, GATA3-AS, LINC01762, LINC01230, LINC01271, LINC01187, LINC00472, AC007849.1, LINC00982, LINC01543, AL031710.1, and AC019197.1 as down-regulated lncRNAs; and SLC16A1-AS1, PVT1, LINC0887, and LUCAT1 as up-regulated lncRNAs. We observed statistically significant dysregulation of PVT1, LUCAT1, and LINC00982. Moreover, we studied the effect of artificial PVT1 decrease in renal cell line 786-0 and observed an effect on cell viability and migration. Conclusion Our results show not only the diagnostic but also the therapeutic potential of PVT1 in renal cell carcinoma.
Links
NV18-03-00554, research and development project |
| ||
90125, large research infrastructures |
| ||
90132, large research infrastructures |
|